Additional long-term biomonitoring, toxicokinetic, and immune-health studies are needed to elucidate the factors influencing the impacts of PFAS exposure on lysozyme activity, it is clear that changes in lysozyme activity alone are insufficient as a biomarker of PFAS-related immunotoxicity. This evidence concerns the gene LYZ and immune system toxicity.